Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that
produce the light-chain forming the amyloid deposits. The plasma cells can be killed and
their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide,
steroids, such as dexamethasone, and drugs that stimulate the immune system, such as
lenalidomide.
The present trial studies the efficacy and safety of the combination of cyclophosphamide,
lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated
and need further therapy.